EVOTEC SE ADR 1/2 O.N. (EVTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, EVOTEC SE ADR 1/2 O.N. (EVTA) has a cash flow conversion efficiency ratio of -0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-67.56 Million ≈ $-78.98 Million USD) by net assets (€800.14 Million ≈ $935.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
EVOTEC SE ADR 1/2 O.N. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how EVOTEC SE ADR 1/2 O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EVTA total debt and obligations for a breakdown of total debt and financial obligations.
EVOTEC SE ADR 1/2 O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EVOTEC SE ADR 1/2 O.N. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
N/A |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SHG:600479
|
0.089x |
|
Wuhan Xingtu Xinke Electronics Co Ltd
SHG:688081
|
-0.047x |
|
Guangzhou Hongli Opto Electron
SHE:300219
|
0.038x |
|
Hangzhou Heshun Technology Co.LTD.
SHE:301237
|
N/A |
|
National Grid PLC
LSE:NG
|
0.076x |
|
Sejin Heavy Industries Co Ltd
KO:075580
|
0.100x |
|
Hubei Century Network Technology Co Ltd
SHE:300494
|
0.014x |
Annual Cash Flow Conversion Efficiency for EVOTEC SE ADR 1/2 O.N. (2021–2024)
The table below shows the annual cash flow conversion efficiency of EVOTEC SE ADR 1/2 O.N. from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see EVTA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €952.52 Million ≈ $1.11 Billion |
€18.22 Million ≈ $21.30 Million |
0.019x | -41.21% |
| 2023-12-31 | €1.12 Billion ≈ $1.31 Billion |
€36.44 Million ≈ $42.60 Million |
0.033x | -81.23% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
€205.81 Million ≈ $240.61 Million |
0.173x | +88.66% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€126.60 Million ≈ $148.01 Million |
0.092x | -- |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more